Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Leadingtac Pharmaceutical (shaoxing) Co., Ltd.

Clinical trials sponsored by Leadingtac Pharmaceutical (shaoxing) Co., Ltd., explained in plain language.

Not yet recruiting 1

New pill targets hard-to-treat cancers with KRAS G12D mutation

Disease control Not yet recruiting

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control

Last updated Jun 11, 2026 12:10 UTC